Hepatocyte growth factor gene therapy
Latest Information Update: 20 Jul 2006
At a glance
- Originator Nonindustrial source
- Class Gene therapies; Growth factors; Vascular disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Hepatocyte growth factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cerebral ischaemia; Liver cirrhosis